Myelodysplastic Syndrome Clinical Trial
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Summary
This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10^9/L in the absence of ITP rescue medications for the past 4 weeks.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines at least 6 months before screening, regardless of splenectomy status
Age ≥ 1 year and < 18 years of age
Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for other therapies. Examples of prior therapy include: corticosteroids, intravenous Immunoglobulin (IVIG), anti-D immunoglobulin, platelet transfusions.
Platelet count ≤ 30 x10^9/L or is experiencing uncontrolled bleeding
Has provided informed consent before any study-specific procedure;
Adequate hematologic, renal, and liver function during screening:
Hemoglobin > 10.0 g/dL
Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)
Total serum bilirubin ≤ 1.5 x the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x the ULN
For the EU, Switzerland and Turkey protocol supplement, subject must agree to a scheduled bone marrow biopsy and aspirate at Year 1 or Year 2 following romiplostim treatment and any unscheduled biopsies if clinically indicated
For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scale, as assessed by central laboratory from a bone marrow biopsy performed within 1 year prior to planned first dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate prior to planned first dose of romiplostim
Exclusion Criteria:
History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled)
Prior bone marrow transplant or peripheral blood progenitor cell transplant
Active or prior malignancy except non-melanoma skin cancers within the last 5 years
History of myelodysplastic syndrome
History of bleeding diathesis
History of congenital thrombocytopenia
History of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV)
History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia
History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant
History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
History of venous thromboembolism or thrombotic events
Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment
Previous use of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other platelet producing agent
Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study
Splenectomy within 4 weeks of the screening visit
Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
Vaccinations known to decrease platelet counts within 8 weeks before the screening visit
Currently enrolled in another investigational device or drug study, or less than 30 days since ending investigational study
Will have investigational procedures while enrolled on study
Female subject of child bearing potential (defined as having first menses) not willing to use, in combination with her partner highly effective methods of birth control during treatment and for 1 month after the end of treatment
Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment
Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg, Infergen®, Neupogen®, somatropin, and Actimmune®)
Has previously enrolled into this study
Will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge
Any kind of disorder that, may compromise the subject to give written informed consent and/or to comply with all required study procedures
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 78 Locations for this study
Roseville California, 95661, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60611, United States
Peoria Illinois, 61615, United States
Indianapolis Indiana, 46260, United States
Iowa City Iowa, 52242, United States
Kansas City Missouri, 64108, United States
Las Vegas Nevada, 89109, United States
New York New York, 10021, United States
Cincinnati Ohio, 45229, United States
Columbus Ohio, 43205, United States
Pittsburgh Pennsylvania, 15224, United States
Nashville Tennessee, 37232, United States
Dallas Texas, 75390, United States
Fort Worth Texas, 76104, United States
Houston Texas, 77030, United States
Randwick New South Wales, 2031, Australia
South Brisbane Queensland, 4101, Australia
Parkville Victoria, 3052, Australia
Brussels , 1020, Belgium
Bruxelles , 1200, Belgium
Gent , 9000, Belgium
Leuven , 3000, Belgium
Liege , 4000, Belgium
Belem Pará, 66033, Brazil
Jau São Paulo, 17210, Brazil
Sao Paulo São Paulo, 05403, Brazil
Sao Paulo São Paulo, 08270, Brazil
Hamilton Ontario, L8S 4, Canada
Toronto Ontario, M5G 1, Canada
Montreal Quebec, H3T 1, Canada
Montreal Quebec, H4A 3, Canada
Olomouc , 775 2, Czechia
Ostrava-Poruba , 708 5, Czechia
Praha 5 , 150 0, Czechia
Montpellier cedex 05 , 34295, France
Nice Cedex 3 , 06202, France
Paris , 75019, France
Vandoeuvre les Nancy , 54511, France
Budapest , 1094, Hungary
Debrecen , 4032, Hungary
Szeged , 6720, Hungary
Beer Sheva , 84101, Israel
Haifa , 31096, Israel
Jerusalem , 91120, Israel
Petach Tikvah , 49202, Israel
Tel Aviv , 64239, Israel
Tel Hashomer , 52621, Israel
Monterrey Nuevo León, 64460, Mexico
Bydgoszcz , 85-09, Poland
Lodz , 91-73, Poland
Olsztyn , 10-56, Poland
Zabrze , 41-80, Poland
Krasnodar , 35000, Russian Federation
Moscow , 11719, Russian Federation
Moscow , 11799, Russian Federation
Saint-Petersburg , 19702, Russian Federation
Saratov , 41002, Russian Federation
Volgograd , 40013, Russian Federation
Johannesburg Gauteng, 2013, South Africa
Parktown Gauteng, 2193, South Africa
Durban KwaZulu-Natal, 4001, South Africa
Tygerberg Western Cape, 7505, South Africa
Barcelona Cataluña, 08035, Spain
Esplugues de Llobregat Cataluña, 08950, Spain
Valencia Comunidad Valenciana, 46026, Spain
Madrid , 28009, Spain
Madrid , 28046, Spain
Basel , 4056, Switzerland
St. Gallen , 9006, Switzerland
Zuerich , 8032, Switzerland
Adana , 01130, Turkey
Antalya , 07059, Turkey
Izmir , 35100, Turkey
Birmingham , B4 6N, United Kingdom
Edinburgh , EH9 1, United Kingdom
London , W12 0, United Kingdom
Manchester , M13 9, United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.